Complementary and alternative medicine (CAM)-products and practices considered outside conventional medicine-are used by 25-50% of adults in developed nations, and among cancer patients its use is described as common and widespread. 1 In the BMT setting, in which narrow therapeutic indexes and drug-drug interactions are commonplace, knowledge of CAM use is crucial.
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We report a patient undergoing myeloablative conditioning before hematopoietic stem cell transplantation (HSCT) with a markedly decreased busulfan (BU) clearance attributed to a CAM product. The patient is a 44-year-old obese man (body mass index: 53 kg/m 2 ) with stage-III (ISS) IgG kappa multiple myeloma. After three cycles of proteasome inhibitor-containing induction chemotherapy, he achieved a partial response per IMWG criteria without significant toxicities. Other than decreased creatinine clearance (53 mL/min) attributed to his myeloma, the pre-HSCT organ function was within normal institutional limits (total bilirubin: 0.2 mg/dL, direct bilirubin: 0.1 mg/dL, alkaline phosphatase: 56 U/L, AST: 16 U/L, ALT: 9 U/L).
The patient's conditioning regimen consisted of pharmacokinetic (PK)-directed, i.v. BU with i.v. bortezomib and melphalan as a part of the clinical trial (ClinicalTrials.gov Identifier: NCT01605032; see Table 1 for details of the conditioning regimen). Aiming to limit BU exposure to a total area-under-the-curve (AUC) of 20 000 mM Â min, a test dose (BU 0.8 mg/kg i.v. infusion over 2 h, actual dose: 166 mg) was administered 6 days (day 12) before the first treatment dose. PK analysis for the test dose showed a BU exposure of AUC 1 202 mM Â min and a clearance rate of 2.70 mL/min/kg. 2 A cumulative exposure AUC of 19 970 mM Â min was predicted to be achieved by administering 651 mg i.v. BU daily over 3 h for 4 consecutive days (see Table 2 for details).
Unbeknownst to providers at the time, the patient consumed 2-3 ounces of the herbal supplement, Flor-Essence, on two occasions after the test-dose administration but before transplant admission. Flor-Essence, a proprietary blend of eight ingredientsArctium lappa/Arctium minus; Rheum palmatum; Rumex acetosella; Ulmus rubra; Nasturtium officinale; Cnicus benedictus; Trifolium pratense; and Laminaria digitata-is manufactured, marketed and sold by Flora Inc. (Lynden, Washington, USA). Four of Flor-Essence ingredients (noted in bold) are also found in the CAM product, Essiac, which has a long history as an alternative cancer treatment, but Flora Inc. makes no explicit anti-cancer claims. 3 Evidence of any anti-cancer effect of Flor-Essence, Essiac, or its individual components is thin. 4 In vitro analysis of some ingredients have shown inhibition of various cytochrome P450 (CYP) enzymes (CYP1A2 by 37%, CYP2C19 by 24%, CYP2C9 by 13%, CYP2D6 by 9% and CYP3A4 by 5%), 5 but little information exists on their effects on glutathione S-transferase (GST) activity or glutathione (GSH) levels. For instance, there are reports that Arctium lappa and phenylethyl isothiocyanate (a major breakdown product of Nasturtium officinale) may increase the GSH level and the hepatic GST activity. 6, 7 In humans, the best described metabolic pathway for BU is via conjugation with hepatic glutathione by GST, 8 and known inhibitors of CYP enzymes, such as itraconazole, have been shown to decrease BU clearance by 20-46%. 9 The patient was admitted to this hospital and conditioning began on day À 6. As per standard procedure, confirmatory PK sampling was performed with this first treatment dose of BU to confirm the accuracy of the estimated AUC determined by the test dose. Day À 6 PK results revealed that the patient's observed AUC was 67% higher than predicted and his clearance had decreased by 40% (AUC 7 838 mM Â min, clearance rate 1.62 mL/ min/kg). Other patients treated with the same protocol had not demonstrated such marked changes in BU clearance (n ¼ 10, own unpublished data). Similarly, other studies using PK-directed BU dosing report relatively consistent clearances (within 15%) between test and regimen dose PK analyses. 10 When neither lab nor sampling error was identified, the patient reported his ingestion of the herbal supplement; however, two doses of BU had already been administered. Continuing the same dose would have resulted in overdosing; thus, in order to achieve the desired AUC of 20 000, dose 3 (day 4) was reduced. Day À 4 PK sampling showed a further 23% decrease in clearance (AUC 5303 mM Â min, clearance rate 1.25 mL/min/kg) so that his total cumulative BU dose was 21 913 mM Â min. The final BU dose (day 3) was not administered. Table 1 . Treatment schema for a protocol-directed conditioning regimen consisting of intravenous BU along with i.v. bortezomib and melphalan
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The higher-than-desired BU exposure did not delay successful engraftment (neutrophils: day 10; platelets: day 8); however, the patient's clinical course was complicated by the greater-thanexpected gastrointestinal (GI) toxicities, including Grade 3 nausea, vomiting, diarrhea and esophagitis. After discharge, profound weight loss and a decreased performance status contributed to the patient's slow recovery to his pretransplant level of functioning. One month post HSCT, the patient was re-hospitalized for dyspnea attributed to either melphalan or BU pulmonary toxicity. Despite a prolonged steroid taper, the patient's respiratory status, although improved, has not returned to baseline at 12 weeks post HSCT.
Given the timing of the patient's Flor-Essence ingestion and the absence of other explanations for his decreased BU clearance, we believe this CAM product led to unexpectedly high BU levels. Although no definite causality between ingestion of Flor-Essence and decreased BU clearance can be established, a CAM-drug interaction is very plausible. Mechanistically, the limited information available suggests that the CYP activity of Flor-Essence ingredients may alter BU disposition in the liver. For providers, this case demonstrates the importance of eliciting a detailed history of all therapeutics, conventional and CAM alike, to achieve optimal dosing of chemotherapeutics. Patients, too, should be educated about the significant interactions medications, foods and CAM products can have with their chemotherapy so as to avoid excessive toxicities and suboptimal dosing and achieve better clinical outcomes. 
